The DOI matches its Crossref record; 94 of the 94 references it cites were found in a registry or an index.
Glioblastoma and Other Primary Brain Malignancies in Adults: A Review
Open accessAbstract
Importance: Malignant primary brain tumors cause more than 15 000 deaths per year in the United States. The annual incidence of primary malignant brain tumors is approximately 7 per 100 000 individuals and increases with age. Five-year survival is approximately 36%. Observations: Approximately 49% of malignant brain tumors are glioblastomas, and 30% are diffusely infiltrating lower-grade gliomas. Other malignant brain tumors include primary central nervous system (CNS) lymphoma (7%) and malignant forms of ependymomas (3%) and meningiomas (2%). Symptoms of malignant brain tumors include headache (50%), seizures (20%-50%), neurocognitive impairment (30%-40%), and focal neurologic deficits (10%-40%). Magnetic resonance imaging before and after a gadolinium-based contrast agent is the preferred imaging modality for evaluating brain tumors. Diagnosis requires tumor biopsy with consideration of histopathological and molecular characteristics. Treatment varies by tumor type and often includes a combination of surgery, chemotherapy, and radiation. For patients with glioblastoma, the combination of temozolomide with radiotherapy improved survival when compared with radiotherapy alone (2-year survival, 27.2% vs 10.9%; 5-year survival, 9.8% vs 1.9%; hazard ratio [HR], 0.6 [95% CI, 0.5-0.7]; P < .001). In patients with anaplastic oligodendroglial tumors with 1p/19q codeletion, probable 20-year overall survival following radiotherapy without vs with the combination of procarbazine, lomustine, and vincristine was 13.6% vs 37.1% (80 patients; HR, 0.60 [95% CI, 0.35-1.03]; P = .06) in the EORTC 26951 trial and 14.9% vs 37% in the RTOG 9402 trial (125 patients; HR, 0.61 [95% CI, 0.40-0.94]; P = .02). Treatment of primary CNS lymphoma includes high-dose methotrexate-containing regimens, followed by consolidation therapy with myeloablative chemotherapy and autologous stem cell rescue, nonmyeloablative chemotherapy regimens, or whole brain radiation. Conclusions and Relevance: The incidence of primary malignant brain tumors is approximately 7 per 100 000 individuals, and approximately 49% of primary malignant brain tumors are glioblastomas. Most patients die from progressive disease. First-line therapy for glioblastoma is surgery followed by radiation and the alkylating chemotherapeutic agent temozolomide.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
The National Comprehensive Cancer Network: Present and future directions
McGivney, W. T. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980515)82:10+<2057::aid-cncr14>3.0.co;2-a · Cited by 16,766
The 2021 WHO classification of tumors of the central nervous system: a summary
Louis, D. N., Perry, A., Wesseling, P., Brat, D. J., Cree, I. A., Figarella-Branger, D., Hawkins, C., Ng, H. K., Pfister, S. M., Reifenberger, G., et al. (2021) · Neuro-Oncology · doi:10.1093/neuonc/noab106 · Cited by 12,273
Ostrom, Q. T., Gittleman, H., Farah, P., Ondracek, A., Chen, Y., Wolinsky, Y., Stroup, N. E., Kruchko, C., & Barnholtz-Sloan, J. S. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not151 · Cited by 11,994
Hao (2015) · doi:10.1002/14651858 · Cited by 11,321
Stupp, R., Hegi, M. E., Mason, W. P., van den Bent, M. J., Taphoorn, M. J., Janzer, R. C., Ludwin, S. K., Allgeier, A., Fisher, B., Belanger, K., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70025-7 · Cited by 7,668
MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043331 · Cited by 7,405
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
Immunotherapy of Diffuse Gliomas: Biological Background, Current Status and Future Developments
Grauer, O. M., Wesseling, P., & Adema, G. J. (2009) · Brain Pathology · doi:10.1111/j.1750-3639.2009.00315.x · Cited by 4,007
Stummer, W., Pichlmeier, U., Meinel, T., Wiestler, O. D., Zanella, F., & Reulen, H.-J. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70665-9 · Cited by 3,423
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas
The Cancer Genome Atlas Research Network (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1402121 · Cited by 3,148
DNA methylation-based classification of central nervous system tumours
Capper, D., Jones, D. T. W., Sill, M., Hovestadt, V., Schrimpf, D., Sturm, D., Koelsche, C., Sahm, F., Chavez, L., Reuss, D. E., et al. (2018) · Nature · doi:10.1038/nature26000 · Cited by 3,033
Stupp, R., Taillibert, S., Kanner, A., Read, W., Steinberg, D. M., Lhermitte, B., Toms, S., Idbaih, A., Ahluwalia, M. S., Fink, K., et al. (2017) · JAMA · doi:10.1001/jama.2017.18718 · Cited by 2,644
Lee, A. Y. Y., Levine, M. N., Baker, R. I., Bowden, C., Kakkar, A. K., Prins, M., Rickles, F. R., Julian, J. A., Haley, S., Kovacs, M. J., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa025313 · Cited by 2,534
Ostrom, Q. T., Cioffi, G., Waite, K., Kruchko, C., & Barnholtz-Sloan, J. S. (2021) · Neuro-Oncology · doi:10.1093/neuonc/noab200 · Cited by 2,529
Glioma Groups Based on 1p/19q,IDH, and TERT Promoter Mutations in Tumors
Eckel-Passow, J. E., Lachance, D. H., Molinaro, A. M., Walsh, K. M., Decker, P. A., Sicotte, H., Pekmezci, M., Rice, T., Kosel, M. L., Smirnov, I. V., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1407279 · Cited by 1,982
Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism
Raskob, G. E., van Es, N., Verhamme, P., Carrier, M., Di Nisio, M., Garcia, D., Grosso, M. A., Kakkar, A. K., Kovacs, M. J., Mercuri, M. F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1711948 · Cited by 1,633
Ostrom, Q. T., Price, M., Neff, C., Cioffi, G., Waite, K. A., Kruchko, C., & Barnholtz-Sloan, J. S. (2022) · Neuro-Oncology · doi:10.1093/neuonc/noac202 · Cited by 1,565
Reardon, D. A., Brandes, A. A., Omuro, A., Mulholland, P., Lim, M., Wick, A., Baehring, J., Ahluwalia, M. S., Roth, P., Bähr, O., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.1024 · Cited by 1,501
Cloughesy, T. F., Mochizuki, A. Y., Orpilla, J. R., Hugo, W., Lee, A. H., Davidson, T. B., Wang, A. C., Ellingson, B. M., Rytlewski, J. A., Sanders, C. M., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0337-7 · Cited by 1,382
Self-citationYoung, A. M., Marshall, A., Thirlwall, J., Chapman, O., Lokare, A., Hill, C., Hale, D., Dunn, J. A., Lyman, G. H., Hutchinson, C., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.8034 · Cited by 1,348
Malmström, A., Grønberg, B. H., Marosi, C., Stupp, R., Frappaz, D., Schultz, H., Abacioglu, U., Tavelin, B., Lhermitte, B., Hegi, M. E., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70265-6 · Cited by 1,286
van den Bent, M. J., Brandes, A. A., Taphoorn, M. J. B., Kros, J. M., Kouwenhoven, M. C. M., Delattre, J.-Y., Bernsen, H. J. J. A., Frenay, M., Tijssen, C. C., Grisold, W., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.2229 · Cited by 1,226
Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma
Perry, J. R., Laperriere, N., O’Callaghan, C. J., Brandes, A. A., Menten, J., Phillips, C., Fay, M., Nishikawa, R., Cairncross, J. G., Roa, W., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611977 · Cited by 1,172
Wen, P. Y., Weller, M., Lee, E. Q., Alexander, B. M., Barnholtz-Sloan, J. S., Barthel, F. P., Batchelor, T. T., Bindra, R. S., Chang, S. M., Chiocca, E. A., et al. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa106 · Cited by 1,168
Self-citationCairncross, G., Wang, M., Shaw, E., Jenkins, R., Brachman, D., Buckner, J., Fink, K., Souhami, L., Laperriere, N., Curran, W., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.2674 · Cited by 1,156
Wick, W., Platten, M., Meisner, C., Felsberg, J., Tabatabai, G., Simon, M., Nikkhah, G., Papsdorf, K., Steinbach, J. P., Sabel, M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70164-x · Cited by 1,135
Brown, T. J., Brennan, M. C., Li, M., Church, E. W., Brandmeir, N. J., Rakszawski, K. L., Patel, A. S., Rizk, E. B., Suki, D., Sawaya, R., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.1373 · Cited by 1,081
Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma
Buckner, J. C., Shaw, E. G., Pugh, S. L., Chakravarti, A., Gilbert, M. R., Barger, G. R., Coons, S., Ricci, P., Bullard, D., Brown, P. D., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1500925 · Cited by 1,064
Roa, W., Brasher, P. M. A., Bauman, G., Anthes, M., Bruera, E., Chan, A., Fisher, B., Fulton, D., Gulavita, S., Hao, C., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.06.082 · Cited by 904
Recurrent Glioblastoma Treated with Recombinant Poliovirus
Desjardins, A., Gromeier, M., Herndon, J. E., Beaubier, N., Bolognesi, D. P., Friedman, A. H., Friedman, H. S., McSherry, F., Muscat, A. M., Nair, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716435 · Cited by 815
Franz, D. N., Belousova, E., Sparagana, S., Bebin, E. M., Frost, M., Kuperman, R., Witt, O., Kohrman, M. H., Flamini, J. R., Wu, J. Y., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61134-9 · Cited by 794
Radiotherapy for Glioblastoma in the Elderly
Keime-Guibert, F., Chinot, O., Taillandier, L., Cartalat-Carel, S., Frenay, M., Kantor, G., Guillamo, J.-S., Jadaud, E., Colin, P., Bondiau, P.-Y., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065901 · Cited by 792
EANO guideline on the diagnosis and management of meningiomas
Goldbrunner, R., Stavrinou, P., Jenkinson, M. D., Sahm, F., Mawrin, C., Weber, D. C., Preusser, M., Minniti, G., Lund-Johansen, M., Lefranc, F., et al. (2021) · Neuro-Oncology · doi:10.1093/neuonc/noab150 · Cited by 742
Belzutifan for Renal Cell Carcinoma in von Hippel–Lindau Disease
Jonasch, E., Donskov, F., Iliopoulos, O., Rathmell, W. K., Narayan, V. K., Maughan, B. L., Oudard, S., Else, T., Maranchie, J. K., Welsh, S. J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2103425 · Cited by 714
Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials
(2015) · Neuro-Oncology · doi:10.1093/neuonc/nov095 · Cited by 663
Ferreri, A. J., Reni, M., Foppoli, M., Martelli, M., Pangalis, G. A., Frezzato, M., Cabras, M. G., Fabbri, A., Corazzelli, G., Ilariucci, F., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61416-1 · Cited by 662
Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma
Schalper, K. A., Rodriguez-Ruiz, M. E., Diez-Valle, R., López-Janeiro, A., Porciuncula, A., Idoate, M. A., Inogés, S., de Andrea, C., López-Diaz de Cerio, A., Tejada, S., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0339-5 · Cited by 642
Molinaro, A. M., Hervey-Jumper, S., Morshed, R. A., Young, J., Han, S. J., Chunduru, P., Zhang, Y., Phillips, J. J., Shai, A., Lafontaine, M., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2019.6143 · Cited by 631
Intratumoral oncolytic herpes virus G47∆ for residual or recurrent glioblastoma: a phase 2 trial
Todo, T., Ito, H., Ino, Y., Ohtsu, H., Ota, Y., Shibahara, J., & Tanaka, M. (2022) · Nature Medicine · doi:10.1038/s41591-022-01897-x · Cited by 526
Omuro, A., Brandes, A. A., Carpentier, A. F., Idbaih, A., Reardon, D. A., Cloughesy, T., Sumrall, A., Baehring, J., van den Bent, M., Bähr, O., et al. (2023) · Neuro-Oncology · doi:10.1093/neuonc/noac099 · Cited by 516
Fangusaro, J., Onar-Thomas, A., Young Poussaint, T., Wu, S., Ligon, A. H., Lindeman, N., Banerjee, A., Packer, R. J., Kilburn, L. B., Goldman, S., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30277-3 · Cited by 507
Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients
Stern, A., Green, H., Paul, M., Vidal, L., & Leibovici, L. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005590.pub3 · Cited by 452
A vaccine targeting mutant IDH1 in newly diagnosed glioma
Platten, M., Bunse, L., Wick, A., Bunse, T., Le Cornet, L., Harting, I., Sahm, F., Sanghvi, K., Tan, C. L., Poschke, I., et al. (2021) · Nature · doi:10.1038/s41586-021-03363-z · Cited by 432
Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma
Grommes, C., Pastore, A., Palaskas, N., Tang, S. S., Campos, C., Schartz, D., Codega, P., Nichol, D., Clark, O., Hsieh, W.-Y., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0613 · Cited by 409
Self-citationvan den Bent, M. J., Baumert, B., Erridge, S. C., Vogelbaum, M. A., Nowak, A. K., Sanson, M., Brandes, A. A., Clement, P. M., Baurain, J. F., Mason, W. P., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31442-3 · Cited by 394
Wen, P. Y., Stein, A., van den Bent, M., De Greve, J., Wick, A., de Vos, F. Y. F. L., von Bubnoff, N., van Linde, M. E., Lai, A., Prager, G. W., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00578-7 · Cited by 369
BRAF Inhibition in BRAFV600-Mutant Gliomas: Results From the VE-BASKET Study
Kaley, T., Touat, M., Subbiah, V., Hollebecque, A., Rodon, J., Lockhart, A. C., Keedy, V., Bielle, F., Hofheinz, R.-D., Joly, F., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.9990 · Cited by 350
Roa, W., Kepka, L., Kumar, N., Sinaika, V., Matiello, J., Lomidze, D., Hentati, D., Guedes de Castro, D., Dyttus-Cebulok, K., Drodge, S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.6606 · Cited by 340
Pajtler, K. W., Mack, S. C., Ramaswamy, V., Smith, C. A., Witt, H., Smith, A., Hansford, J. R., von Hoff, K., Wright, K. D., Hwang, E., et al. (2017) · Acta Neuropathologica · doi:10.1007/s00401-016-1643-0 · Cited by 337
Surgical oncology for gliomas: the state of the art
Sanai, N., & Berger, M. S. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.171 · Cited by 332
Health-related quality of life in patients with glioblastoma: a randomised controlled trial
Taphoorn, M. J., Stupp, R., Coens, C., Osoba, D., Kortmann, R., van den Bent, M. J., Mason, W., Mirimanoff, R. O., Baumert, B. G., Eisenhauer, E., et al. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70432-0 · Cited by 331
van den Bent, M. J., Tesileanu, C. M. S., Wick, W., Sanson, M., Brandes, A. A., Clement, P. M., Erridge, S., Vogelbaum, M. A., Nowak, A. K., Baurain, J. F., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00090-5 · Cited by 330
Ivosidenib in Isocitrate Dehydrogenase 1–Mutated Advanced Glioma
Mellinghoff, I. K., Ellingson, B. M., Touat, M., Maher, E., De La Fuente, M. I., Holdhoff, M., Cote, G. M., Burris, H., Janku, F., Young, R. J., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03327 · Cited by 324
Self-citationRisk factors for childhood and adult primary brain tumors
Ostrom, Q. T., Fahmideh, M. A., Cote, D. J., Muskens, I. S., Schraw, J. M., Scheurer, M. E., & Bondy, M. L. (2019) · Neuro-Oncology · doi:10.1093/neuonc/noz123 · Cited by 314
Ionizing radiation and the risk of brain and central nervous system tumors: a systematic review
Braganza, M. Z., Kitahara, C. M., Berrington de Gonzalez, A., Inskip, P. D., Johnson, K. J., & Rajaraman, P. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos208 · Cited by 303
Oncolytic DNX-2401 Virus for Pediatric Diffuse Intrinsic Pontine Glioma
Pérez‐Larraya, J. G., García-Moure, M., Labiano, S., Patiño‐García, A., Dobbs, J., González-Huarriz, M., Zalacaín, M., Marrodán, L., Martínez-Vélez, N., Puigdelloses, M., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2202028 · Cited by 300
EANO guidelines for the diagnosis and treatment of ependymal tumors
Rudà, R., Reifenberger, G., Frappaz, D., Pfister, S. M., Laprie, A., Santarius, T., Roth, P., Tonn, J. C., Soffietti, R., Weller, M., et al. (2018) · Neuro-Oncology · doi:10.1093/neuonc/nox166 · Cited by 299
European Association for Neuro-Oncology (EANO) guidelines for palliative care in adults with glioma
Pace, A., Dirven, L., Koekkoek, J. A. F., Golla, H., Fleming, J., Rudà, R., Marosi, C., Rhun, E. L., Grant, R., Oliver, K., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30345-5 · Cited by 297
Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma
Kaley, T. J., Wen, P., Schiff, D., Ligon, K., Haidar, S., Karimi, S., Lassman, A. B., Nolan, C. P., DeAngelis, L. M., Gavrilovic, I., et al. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nou148 · Cited by 294
Houillier, C., Taillandier, L., Dureau, S., Lamy, T., Laadhari, M., Chinot, O., Moluçon-Chabrot, C., Soubeyran, P., Gressin, R., Choquet, S., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.00306 · Cited by 287
Mellinghoff, I. K., Penas-Prado, M., Peters, K. B., Burris, H. A., Maher, E. A., Janku, F., Cote, G. M., de la Fuente, M. I., Clarke, J. L., Ellingson, B. M., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0611 · Cited by 271
Self-citationMutant IDH1 and seizures in patients with glioma
Chen, H., Judkins, J., Thomas, C., Wu, M., Khoury, L., Benjamin, C. G., Pacione, D., Golfinos, J. G., Kumthekar, P., Ghamsari, F., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000003911 · Cited by 263
PERRY, J. R., JULIAN, J. A., LAPERRIERE, N. J., GEERTS, W., AGNELLI, G., ROGERS, L. R., MALKIN, M. G., SAWAYA, R., BAKER, R., FALANGA, A., et al. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2010.03973.x · Cited by 249
Miller, J. J., Gonzalez Castro, L. N., McBrayer, S., Weller, M., Cloughesy, T., Portnow, J., Andronesi, O., Barnholtz-Sloan, J. S., Baumert, B. G., Berger, M. S., et al. (2023) · Neuro-Oncology · doi:10.1093/neuonc/noac207 · Cited by 242
Self-citationPrimary central nervous system lymphoma
Schaff, L. R., & Grommes, C. (2022) · Blood · doi:10.1182/blood.2020008377 · Cited by 222
Self-citationIorio, A., & Agnelli, G. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.15.2327 · Cited by 220
A molecularly integrated grade for meningioma
Driver, J., Hoffman, S. E., Tavakol, S., Woodward, E., Maury, E. A., Bhave, V., Greenwald, N. F., Nassiri, F., Aldape, K., Zadeh, G., et al. (2022) · Neuro-Oncology · doi:10.1093/neuonc/noab213 · Cited by 220
Bell, E. H., Zhang, P., Shaw, E. G., Buckner, J. C., Barger, G. R., Bullard, D. E., Mehta, M. P., Gilbert, M. R., Brown, P. D., Stelzer, K. J., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02983 · Cited by 219
Wrensch, M., Lee, M., Miike, R., Newman, B., Bargar, G., Davis, R., Wiencke, J., & Neuhaus, J. (1997) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a009154 · Cited by 218
Tsien, C. I., Pugh, S. L., Dicker, A. P., Raizer, J. J., Matuszak, M. M., Lallana, E. C., Huang, J., Algan, O., Deb, N., Portelance, L., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.00164 · Cited by 213
Evidence-based recommendations on categories for extent of resection in diffuse glioma
Karschnia, P., Vogelbaum, M. A., van den Bent, M., Cahill, D. P., Bello, L., Narita, Y., Berger, M. S., Weller, M., & Tonn, J.-C. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.03.002 · Cited by 212
(2002) · PubMed Central · Cited by 198
Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series
Lou, E., Sumrall, A. L., Turner, S., Peters, K. B., Desjardins, A., Vredenburgh, J. J., McLendon, R. E., Herndon, J. E., McSherry, F., Norfleet, J., et al. (2012) · Journal of Neuro-Oncology · doi:10.1007/s11060-012-0861-0 · Cited by 196
Prevalence and prognostic significance of epilepsy in patients with gliomas
Lote, K., Stenwig, A. E., Skullerud, K., & Hirschberg, H. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(97)00374-2 · Cited by 185
Jonsson, P., Lin, A. L., Young, R. J., DiStefano, N. M., Hyman, D. M., Li, B. T., Berger, M. F., Zehir, A., Ladanyi, M., Solit, D. B., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0032 · Cited by 171
Self-citationWalbert, T., Harrison, R. A., Schiff, D., Avila, E. K., Chen, M., Kandula, P., Lee, J. W., Le Rhun, E., Stevens, G. H. J., Vogelbaum, M. A., et al. (2021) · Neuro-Oncology · doi:10.1093/neuonc/noab152 · Cited by 162
Hoang-Xuan, K., Deckert, M., Ferreri, A. J. M., Furtner, J., Gallego Perez-Larraya, J., Henriksson, R., Hottinger, A. F., Kasenda, B., Lefranc, F., Lossos, A., et al. (2023) · Neuro-Oncology · doi:10.1093/neuonc/noac196 · Cited by 162
Islim, A. I., Mohan, M., Moon, R. D. C., Srikandarajah, N., Mills, S. J., Brodbelt, A. R., & Jenkinson, M. D. (2019) · Journal of Neuro-Oncology · doi:10.1007/s11060-019-03104-3 · Cited by 154
Amirian, E. S., Zhou, R., Wrensch, M., Olson, S. H., Scheurer, M. E., Il’yasova, D., Lachance, D. H., Armstrong, G., Mccoy, L. S., Lau, C. C., et al. (2016) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-15-0847 · Cited by 150
Seizure control as a new metric in assessing efficacy of tumor treatment in low-grade glioma trials
Avila, E. K., Chamberlain, M. C., Schiff, D., Reijneveld, J. C., Armstrong, T. S., Rudà, R., Wen, P. Y., Weller, M., Koekkoek, J. A. F., Mittal, S., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now190 · Cited by 139
Ependymoma: Evaluation and Management Updates
Rudà, R., Bruno, F., Pellerino, A., & Soffietti, R. (2022) · Current Oncology Reports · doi:10.1007/s11912-022-01260-w · Cited by 129
Brastianos, P. K., Twohy, E. L., Gerstner, E. R., Kaufmann, T. J., Iafrate, A. J., Lennerz, J. K., Jeyapalan, S. A., Piccioni, D. E., Monga, V., Fadul, C. E., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02371 · Cited by 119
Bi, W. L., Nayak, L., Meredith, D. M., Driver, J., Du, Z., Hoffman, S. E., Li, Y. Y., Lee, E. Q., Beroukhim, R., Rinne, M. L., et al. (2021) · Neuro-Oncology · doi:10.1093/neuonc/noab118 · Cited by 107
Lassman, A. B., Hoang‐Xuan, K., Polley, M. C., Brandes, A. A., Cairncross, J. G., Kros, J. M., Ashby, L. S., TAPHOORN, M. J. B., Souhami, L., Dinjens, W. N. M., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02543 · Cited by 104
Molecular Biomarker Testing for the Diagnosis of Diffuse Gliomas
Brat, D. J., Aldape, K., Bridge, J. A., Canoll, P., Colman, H., Hameed, M. R., Harris, B. T., Hattab, E. M., Huse, J. T., Jenkins, R. B., et al. (2022) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2021-0295-cp · Cited by 82
Cellular Telephone Use and the Risk of Brain Tumors: Update of the UK Million Women Study
Schüz, J., Pirie, K. L., REEVES, G. K., Floud, S., Beral, V., & Collaborators, F. T. M. W. S. (2022) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djac042 · Cited by 60
Optimal Management of Corticosteroids in Patients with Intracranial Malignancies
Dixit, K., & Kumthekar, P. (2020) · Current Treatment Options in Oncology · doi:10.1007/s11864-020-00771-7 · Cited by 51
Quantifying the heritability of glioma using genome-wide complex trait analysis
Kinnersley, B., Mitchell, J. S., Gousias, K., Schramm, J., Idbaïh, A., Labussière, M., Marie, Y., Rahimian, A., Wichmann, H. ‐., Schreiber, S., et al. (2015) · Scientific Reports · doi:10.1038/srep17267 · Cited by 48
Letter: When Less is More: Dexamethasone Dosing for Brain Tumors
Lim-Fat, M. J., Bi, W. L., Lo, J., Lee, E. Q., Ahluwalia, M. S., Batchelor, T. T., Chang, S. M., Chiocca, E. A., Chukwueke, U. N., Cloughesy, T. F., et al. (2019) · Neurosurgery · doi:10.1093/neuros/nyz186 · Cited by 33
Self-citationReed-Guy, L., Desai, A. S., Phillips, R. E., Croteau, D., Albright, K., O’Neill, M., Brem, S. S., O’Rourke, D. M., Amankulor, N., & Bagley, S. J. (2022) · Neuro-Oncology · doi:10.1093/neuonc/noac125 · Cited by 33
Venous thromboembolic events in glioblastoma patients: An epidemiological study
Eisele, A., Seystahl, K., Rushing, E. J., Roth, P., Rhun, É. L., Weller, M., & Gramatzki, D. (2022) · European Journal of Neurology · doi:10.1111/ene.15404 · Cited by 26
Mellinghoff, I. K., & Cloughesy, T. F. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02166 · Cited by 21
Self-citationDo Cell Phones Cause Brain Tumors? Another Piece of the Puzzle
Weed, D. L. (2022) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djac043 · Cited by 5
Cited by
Glioblastoma Therapy: Past, Present and Future
Obrador, E., Moreno-Murciano, P., Oriol-Caballo, M., López-Blanch, R., Pineda, B., Gutiérrez-Arroyo, J., Loras, A., Gonzalez-Bonet, L., Martinez-Cadenas, C., Estrela, J., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052529 · Cited by 271
Zhang, Y., Kang, X., Ma, J., Li, J., Chen, W., Yang, S., Li, W., Shi, Y., & Qi, J. (2025) · Advanced Functional Materials · doi:10.1002/adfm.202419395 · Cited by 20
Wei, H., Zhang, S., Tao, S., Li, J., & Liu, X. (2026) · Asia-Pacific Journal of Oncology Nursing · doi:10.1016/j.apjon.2026.100978 · Cited by 2
Metadata
- Authors
- Schaff, L. R., & Mellinghoff, I. K.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2023-02-21
- Volume
- 329
- Issue
- 7
- Pages
- 574
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W4321445965
- Cited by
- 1,271
- References
- 94
- FWCI
- 181.63
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.